Although the authors reported comparable response charges amongst the two teams, as anticipated, cardiotoxicity was far much less in the PLD arm. Myelosuppression and hepatotoxicity are significant antagonistic events. The FDA granted accelerated approval to Pembrolizumab in May of 2017 for adult and pediatric patients with unresectable or metastatic stable tumors that exhibit MSI-H or...More Please